Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
NeoPhore Ltd logo — Discovering drugs that create neoantigens

NeoPhore Ltd

Discovering drugs that create neoantigens

Founded 2017 United Kingdom Cambridge, United Kingdom 18 employees Series B Total: $33.80M Biotechnology, Health and Wellness

General Information

Company Name NeoPhore Ltd
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 18
Industries Biotechnology, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with NeoPhore Ltd. To contact NeoPhore Ltd, visit neophore.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NeoPhore Ltd compare?

A PDF of NeoPhore Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NeoPhore Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NeoPhore Ltd

NeoPhore Ltd is a biotechnology startup headquartered in the United Kingdom, founded in 2017. The company's focus is on creating novel small molecule immuno-oncology therapeutics. Their drugs target genetic mechanisms that have been validated in both clinical and lab studies for promoting neoantigen creation and diversity across various cancers. This innovative approach aims to stimulate the immune system and improve patient outcomes, particularly for those who have not benefited from current cancer immunity therapeutics. NeoPhore recently received a Series B investment on 22nd May 2024, with the renowned pharmaceutical company Bristol-Myers Squibb as one of the investors. Through their groundbreaking work in discovering drugs that create neoantigens, NeoPhore is poised to make a significant impact in the field of cancer treatment.

Business keywords: immuno-oncology, small molecule therapeutics, neoantigen creation, genetic mechanisms, cancer immunotherapy, immune system stimulation, cancer treatment, drug development, cancer therapy, clinical validation, lab studies, oncology, drug targeting, patient outcomes, cancer research

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 1
Bristol-Myers Squibb
22 May 2024
Series B £9.60M 8
3B Future Health Fund Astellas Venture Management LIFTT
3B Future Health Fund, Astellas Venture Management +6
01 Feb 2024
Series B £6.00M 5
3B Future Health Fund Astellas Venture Management
3B Future Health Fund, Astellas Venture Management +3
19 Jan 2023
Series B £15.20M 5
3B Future Health Fund Astellas Venture Management
3B Future Health Fund, Astellas Venture Management +3
09 Mar 2021
Grant Undisclosed 1
Innovate UK
Innovate UK
27 Apr 2018
Venture Round £3.00M 1
Sixth Element Capital
16 Nov 2017

NeoPhore Ltd Alternatives & Competitors

View All Alternatives
NeoPhore Ltd vs
Odimma Therapeutics
Odimma Therapeutics France

Empowering Personalized Immunotherapy to Treat Cancer

Seed
6 employees
Biotechnology, Health Care
NeoPhore Ltd vs
Quentis Therapeutics
Quentis Therapeutics

Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the f...

Grant
Biotechnology, Health Care
NeoPhore Ltd vs
Geneos Therapeutics
Geneos Therapeutics United States

Developing the next generation of patient specific neoantigen-targeting cancer immunotherapies, one...

Series A
13 employees
Biotechnology, Health Care
View all alternatives

FAQ About NeoPhore Ltd

Discovering drugs that create neoantigens
NeoPhore Ltd was founded in 2017.
NeoPhore Ltd is headquartered in Cambridge, United Kingdom.
NeoPhore Ltd operates in Biotechnology and Health and Wellness. Its work centres on immuno-oncology, small molecule therapeutics, neoantigen creation and genetic mechanisms.
NeoPhore Ltd has approximately 18 employees.
NeoPhore Ltd has completed 6 funding rounds, raising a total of $33.80M. The latest funding stage is Series B.
Top alternatives and competitors to NeoPhore Ltd include Odimma Therapeutics, Quentis Therapeutics, Geneos Therapeutics, Werewolf Therapeutics, Prescient Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeoPhore Ltd and Odimma Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NeoPhore Ltd, https://bouncewatch.com/company/neophore-ltd, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes